Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Sun Pharmaceutical Industries

Growth unavailable

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, as stated in the company's press release

Reported revenue (₹ million): Not available

Read summary and comparison caveats

Sun Pharma reported September-quarter consolidated sales of ₹161,000 million, up 11.8%, and EBITDA of ₹47,439 million, up 4.8%. Net profit was ₹19,885 million. The company also reports an adjusted net profit of ₹31,620 million.

  • Source: Sun Pharma's press release dated 30 Oct 2026. Values are in ₹ million as printed (₹10 million = ₹1 crore). The release gives growth percentages but no year-ago values, so the changes shown are the company's own and we computed none.
  • The release does not explain the gap between net profit and adjusted net profit in the sections we read. Adjusted net profit is the company's own measure. Treat the two as different figures.
  • The release is marked consolidated. We did not read the audit or limited-review status.
  • This page is a selected set of checked results, not complete market coverage.

Checked 2 Nov 2026

Open original filing
Read the complete published results desk